European-listed shares of drugmakers Haleon /zigman2/quotes/236012088/delayed UK:HLN +1.57% , GSK /zigman2/quotes/200381158/delayed UK:GSK -0.11% and Sanofi /zigman2/quotes/206928357/delayed FR:SAN +0.53% plunged on Thursday on worries over the Zantac heartburn medication litigation. The first trial is set to begin on Aug. 22. GSK shares dropped 10% in London, as Sanofi and Haleon also dropped sharply. Analysts at Deutsche Bank said they don't expect another glyphosate, but "it is very possible we may see a liability of some billions of dollar magnitude incurred." Analysts at Credit Suisse note Haleon's prospectus says indemnification "may" include liabilities from Zantac.